Quadrasphere Microspheres
Device
Merit Medical Systems Inc
Total Payments
$583,855
Transactions
191
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $41,647 | 25 | 0 |
| 2020 | $60,003 | 37 | 0 |
| 2019 | $47,140 | 47 | 0 |
| 2018 | $165,658 | 63 | 0 |
| 2017 | $269,407 | 19 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $583,855 | 191 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer (HiQuality) | Merit Medical Systems Inc | $462,205 | 0 |
| HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer | Merit Medical Systems Inc | $101,650 | 0 |
| A Retrospective Study of Outcomes for Patients Treated with Quadrasphere Microspheres | Merit Medical Systems Inc | $19,150 | 0 |
| A RETROSPECTIVE STUDY OF OUTCOMES FOR PATIENTS TREATED WITH QUADRASPHERE/HEPASPHERE MICROSPHERES FOR TUMORS IN THE LIVER | Merit Medical Systems Inc | $850.00 | 0 |
Top Doctors Receiving Payments for Quadrasphere Microspheres
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Philadelphia, PA | $583,855 | 191 |
Ad
Manufacturing Companies
- Merit Medical Systems Inc $583,855
Product Information
- Type Device
- Total Payments $583,855
- Total Doctors 0
- Transactions 191
About Quadrasphere Microspheres
Quadrasphere Microspheres is a device associated with $583,855 in payments to 0 healthcare providers, recorded across 191 transactions in the CMS Open Payments database. The primary manufacturer is Merit Medical Systems Inc.
Payment data is available from 2017 to 2021. In 2021, $41,647 was paid across 25 transactions to 0 doctors.
The most common payment nature for Quadrasphere Microspheres is "Unspecified" ($583,855, 100.0% of total).
Quadrasphere Microspheres is associated with 4 research studies, including "HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer (HiQuality)" ($462,205).